PATENT CLAIM ANALYSIS

Application Number: 16090415
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "571000"]

Abstract:
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Claim (Index 16):
Elafibranor for use according to  claim 7 , for oral administration once daily at a dose of 80 or 120 mg/day, in particular to a patient with PBC with inadequate response to UDCA.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.06061
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15496875', '16032380', '16030141', '15720849', '15903279']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7699341473760603
- 35 USC 102 Novelty (BERT): 0.5425580746297677
- Combined Prediction Score: 0.747196540101431
- Mean Citation Score: 335.005982
- Max Citation Score: 368.9588
- Similarity Product: 219.9214202723503

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test